Company Overview and News
Akamai Technologies (AKAM - Free Report) joined forces with Mitsubishi UFJ Financial Group Inc. (MUFG - Free Report) to deliver a new hyper-scale online payment network in Japan by first half of 2020. The payment network will be designed and deployed on Akamai Intelligent Platform and leverage blockchain architecture.
With Japan’s quarterly reporting period almost over, one analyst summed up the general feeling about companies’ profit performance.
Last week, Barclays (BCS - Free Report) acquired £4.3 billion ($5.8 billion) worth of Irish residential mortgage loans from Lloyds Banking Group (LYG - Free Report) . The portfolio comprises around 27,000 mortgages, originated between 2004 and 2010. Of the total loans acquired, nearly £300 million are impaired. Mortgage loan portfolio incurred a pre-tax loss of roughly £40 million in 2017. Notably, Lloyds is expected to record £110 million in pre-tax loss on the deal in second-quarter 2018.
May 17 (Reuters) - Mitsubishi UFJ Financial Group Inc said on Thursday Jon Lindenberg has been promoted to head of investment banking for the Americas.
The following slide deck was published by Mitsubishi UFJ Financial Group, Inc. in conjunction with their 2017 Q4 earnings call.
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average rose on Thursday after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields while tech shares attracted buyers after the yen weakened.
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average followed U.S. stocks higher on Thursday morning after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TOKYO, May 16 (Reuters) - Japanese stocks edged lower on Wednesday as sentiment was knocked by a surge in U.S. Treasury yields to seven-year highs and after Pyongyang called off talks with Seoul, throwing a major U.S.-North Korean summit into question.
TOKYO, May 16 (Reuters) - Japanese stocks edged lower on Wednesday morning as sentiment was knocked by a surge in U.S. Treasury yields to seven-year highs and after Pyongyang called off talks with Seoul, throwing a major U.S.-North Korean summit into question.
Mitsubishi UFJ Financial Group Inc. (MUFG - Free Report) reported profits attributable to owners of parent for fiscal 2017 (ended Mar 31), of ¥989.6 billion ($8.9 billion), up 6.8% year over year. Notably, results exceeded the company’s target of ¥950 billion. For the period under review, low credit costs and strong capital drove the results, while elevated general & administrative expenses, decreased gross profits and decline in net interest income acted as headwinds.
TOKYO, May 15 (Reuters) - Japanese stocks pulled back from a recent 3-1/2 month high on Tuesday, hit by profit-taking, though bank shares staged a rally on hopes of strong earnings for the sector.
Japanese stocks pulled back from 3-1-/2-month highs on Tuesday morning, though bank shares staged a rally on hopes of strong earnings for the sector.
TOKYO, May 15 (Reuters) - Japanese stocks pulled back from 3-1-/2-month highs on Tuesday morning, though bank shares staged a rally on hopes of strong earnings for the sector.
Asian shares looked set for a mixed start on Tuesday after U.S. stock indexes recorded gains amid an improvement in sentiment over U.S.-China trade developments.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...